SCHEMBL3084004

SCHEMBL3084004

CCC(CC)(C(N)=O)C(N)=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 3/20 0.36
LMNA P02545 4/20 0.35
BLM P54132 2/20 0.35
PMP22 Q01453 2/20 0.35
ALDH1A1 P00352 4/20 0.32
CYP1A2 P05177 2/20 0.32
MEN1 O00255 1/20 0.32
THRB P10828 1/20 0.32
KMT2A Q03164 1/20 0.32
TDP1 Q9NUW8 4/20 0.32
FFAR3 O14843 1/20 0.32
OR51E2 Q9H255 1/20 0.31
HSD17B10 Q99714 2/20 0.31
KDM4E B2RXH2 1/20 0.30
GMNN O75496 1/20 0.30
USP2 O75604 1/20 0.30
TP53 P04637 1/20 0.30
GLA P06280 1/20 0.30
POLB P06746 1/20 0.30
CYP3A4 P08684 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4402725 0.97 ALOX15 (0.35) ALOX15LMNABLMPMP22ALDH1A1
Hydrochloric Acid SCHEMBL11512823 0.97 ALOX15 (0.35) ALOX15LMNABLMPMP22ALDH1A1
SCHEMBL3417933 0.88 ALOX15 (0.33) ALOX15LMNABLMPMP22ALDH1A1
SCHEMBL8604881 0.85 KMT2A (0.38) ALOX15LMNABLMPMP22ALDH1A1
SCHEMBL56984 0.85 ALOX15 (0.37) ALOX15LMNABLMPMP22ALDH1A1
SCHEMBL15821652 0.83 ALOX15 (0.31) ALOX15
Hydrochloric Acid SCHEMBL11512818 0.83 MEN1 (0.37) ALOX15ALDH1A1CYP1A2MEN1THRB
Hydrochloric Acid SCHEMBL4402723 0.83 MEN1 (0.37) ALOX15ALDH1A1CYP1A2MEN1THRB
SCHEMBL29375892 0.83 LMNA (0.40) ALOX15LMNAALDH1A1CYP1A2MEN1
SCHEMBL13545109 0.83 TDP1 (0.32) ALOX15ALDH1A1TDP1FFAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120037794-A Preparation method and application of solvent-resistant polyamide composite membrane 南京工业大学 2025-05-27 CN claimed
US-4925662-A ANTITUMOR AGENT BONDED TO HUMAN IMMUNOGLOBULIN KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1990-05-15 US claimed
US-4738843-A Anti-tumor substance of immunoglobulin and melphalan and process for producing the same KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1988-04-19 US claimed
EP-0122132-A2 Anti-tumour substance KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1984-10-17 EP claimed
CN-120037794-A Preparation method and application of solvent-resistant polyamide composite membrane 南京工业大学 2025-05-27 CN disclosed
CN-113462278-B Varnish composition, method for producing polyimide resin, and additive 东京应化工业株式会社 2024-06-07 CN disclosed
CN-116988179-A Preparation method of stock solution coloring acrylic black fiber and fiber thereof 河北吉藁化纤有限责任公司 2023-11-03 CN disclosed
CN-116876096-A Black color paste for acrylic fiber and preparation method thereof 河北吉藁化纤有限责任公司 2023-10-13 CN disclosed
CN-112755193-A Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof 德玛医药 2021-05-07 CN disclosed
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
US-RE33188-E Peptides for assaying human parathyroid hormone TOYO JOZO KABUSHIKI KAISHA (JP) 1990-03-27 US disclosed
EP-0197521-B1 IMMUNOGLOBULIN ADSORBENT AND ADSORPTION APPARATUS TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION (JP) 1989-08-02 EP disclosed
EP-0312360-A2 25-Hydroxy vitamin D3 derivatives TOYO JOZO KABUSHIKI KAISHA (JP) 1989-04-19 EP disclosed
US-4738843-A Anti-tumor substance of immunoglobulin and melphalan and process for producing the same KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1988-04-19 US disclosed
US-4705628-A SILICA GEL REACTED WITH DIAMINE, SILANE COUPLER, SULFA DRUG TERUMO KABUSHIKI KAISHA (JP) 1987-11-10 US disclosed
EP-0197521-A2 Immunoglobulin adsorbent and adsorption apparatus TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION (JP) 1986-10-15 EP disclosed
EP-0122132-A2 Anti-tumour substance KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1984-10-17 EP disclosed
US-4409141-A Peptides for assaying human parathyroid hormone TOYO JOZO KABUSHIKI KAISHA (JP) 1983-10-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 ALOX15 1117/4885LMNA 3803/4885BLM 4214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.